Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Teladoc Health Inc (TDOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Teladoc Health Inc — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.87B), while Teladoc Health Inc trades at $5.79 (market cap $1.09B). The key difference: Kymera Therapeutics Inc. Common Stock is far larger — about 8.1× Teladoc Health Inc's market cap, and Kymera Therapeutics Inc. Common Stock is trading nearer its 52-week high, Teladoc Health Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Teladoc Health Inc for 39 Days on average.
| KYMR | TDOC | |
|---|---|---|
Market Cap | $8.87B | $1.09B |
Volume | 779,107 | 4,279,268 |
Sector | Health | Health |
52-Week High | $127.31 | $9.72 |
52-Week Low | $55.80 | $4.47 |
Typical Hold Time | 0 Days | 39 Days |
Enterprise Value | $8.26B | $1.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Teladoc Health trades at $6.00, showing modest daily gains but remains near multi-year lows with bearish technical signals. The company maintains strong revenue around $2.5B annually but continues posting net losses, though improving from historical levels. Recent management changes and ongoing BetterHelp challenges create uncertainty, while the Integrated Care segment shows promise. Valuation metrics appear attractive with P/S of 0.43 and P/B of 0.83, suggesting potential undervaluation if profitability improves.
The stock presents a high-risk opportunity with significant upside potential if management can stabilize operations and achieve profitability. Analyst consensus targets $8.83 (47% upside) with no sell ratings, but execution risks remain elevated. Key catalysts include successful CFO transition, BetterHelp stabilization, and Integrated Care margin expansion. Investors should weigh the attractive valuation against persistent losses and competitive pressures in telehealth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Teladoc Health Inc
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →
